BCDA

What one share of BioCardia holds

Biological Products, (No Diagnostic Substances)

BioCardia’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.

Per-share figures
Profit−$0.74
Capex (buildings and equipment)$0.00
Free cash flow−$0.76
Cash and investments$0.27
Book value$0.18

Per share by fiscal year

YearSalesProfitCapexFree cashDividendsBook value
2016$9.29−$166.32————
2017$1.69−$43.54$0.48−$31.16—$39.30
2018$2.20−$49.20$0.23−$39.17—$11.74
2019$1.89−$39.09$0.39−$25.49—$5.21
2020$0.21−$22.24$0.05−$18.37—$17.65
2021$0.90−$11.19$0.10−$9.29—$9.22
2022$1.14−$10.08$0.06−$9.00—$3.65
2023$0.34−$8.19$0.01−$7.07—−$1.02
2024$0.02−$2.90$0.00−$2.88—$0.18
2025$0.00−$1.23$0.00−$1.12—$0.08

Common questions about BioCardia

How much does one share of BioCardia earn?

Over the last 12 months, BioCardia lost $0.74 for each share.

Does BioCardia pay a dividend?

BioCardia didn’t pay a dividend over the last 12 months, according to its SEC filings.

What is BioCardia’s book value per share?

BioCardia’s book value is $0.18 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.

How much cash and debt does each share of BioCardia have?

Each share of BioCardia has $0.27 of cash and investments, as of June 30, 2026.

What is BioCardia’s free cash flow per share?

−$0.76 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.

Has BioCardia bought back shares?

BioCardia’s share count rose about 10655% from 2016 to 2025. That dilution means each share owns a smaller slice of the company.

From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.